Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma

NCT01898715 is registered in ClinicalTrials.gov with Millendo Therapeutics, Inc. as lead sponsor.

NCT NCT01898715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01898715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
Lead sponsor
Millendo Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 13, 2013
Completion date
October 17, 2017
Enrollment
63 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acc, adrenal cancer, adrenocortical carcinoma